Jordyn Sava is an assistant editor for Targeted Oncology.
First PSMA PET Set to Improve Imaging in the Prostate Cancer FieldFebruary 15th 2022
In an interview with Targeted Oncology, Bridget Koontz, MD, United States chief medical officer and deputy global chief medical officer at GenesisCare, discusses 18F-DCFPyL and how the well-tolerated agent can change the way prostate cancer patients are treated
Positive Results Correlate With Use of Darolutamide in nmCRPCFebruary 10th 2022
In an interview with Targeted Oncology, Neal Shore discusses the findings of ARAMIS which looked at darolutamide in men with high-risk non-metastatic castration-resistant prostate cancer, and its primary end point of metastasis-free survival.
KEYNOTE-522 Shows Prolonged EFS With Adjuvant Pembrolizumab in High-Risk, Early-Stage TNBCFebruary 10th 2022
In KEYNOTE-522, treatment with adjuvant pembrolizumab following neoadjuvant pembrolizumab with chemotherapy showed a statistically significant prolonged event-free survival in patients with high-risk early-stage triple-negative breast cancer.